ALLK [NASD]
Allakos Inc.
Index- P/E- EPS (ttm)-6.76 Insider Own2.40% Shs Outstand85.20M Perf Week10.60%
Market Cap691.90M Forward P/E- EPS next Y-2.06 Insider Trans218.58% Shs Float81.62M Perf Month43.82%
Income-371.30M PEG- EPS next Q-0.57 Inst Own87.30% Short Float / Ratio2.59% / 1.31 Perf Quarter90.19%
Sales- P/S- EPS this Y-61.70% Inst Trans68.52% Short Interest2.11M Perf Half Y177.82%
Book/sh5.92 P/B1.38 EPS next Y60.00% ROA-92.50% Target Price6.83 Perf Year-89.00%
Cash/sh3.83 P/C2.13 EPS next 5Y29.50% ROE-116.70% 52W Range2.54 - 86.95 Perf YTD-16.85%
Dividend- P/FCF- EPS past 5Y-64.00% ROI- 52W High-90.77% Beta0.51
Dividend %- Quick Ratio12.30 Sales past 5Y- Gross Margin- 52W Low216.57% ATR0.44
Employees192 Current Ratio12.30 Sales Q/Q- Oper. Margin- RSI (14)64.89 Volatility5.66% 6.95%
OptionableYes Debt/Eq0.00 EPS Q/Q54.30% Profit Margin- Rel Volume0.30 Prev Close8.14
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.62M Price8.02
Recom3.00 SMA207.81% SMA5021.47% SMA20066.46% Volume205,380 Change-1.41%
Sep-12-22Downgrade SMBC Nikko Neutral → Underperform $2
Dec-22-21Downgrade William Blair Outperform → Mkt Perform
Dec-22-21Downgrade SVB Leerink Outperform → Mkt Perform $17
Dec-22-21Downgrade Jefferies Buy → Hold
Dec-22-21Downgrade Cowen Outperform → Market Perform
Dec-22-21Downgrade BofA Securities Buy → Underperform $155 → $12
Aug-26-21Initiated Morgan Stanley Equal-Weight $88
Jul-15-21Initiated Cowen Outperform
May-18-21Initiated H.C. Wainwright Buy $230
Feb-24-21Initiated Cantor Fitzgerald Overweight $218
Show Previous Ratings
Nov-29-22 07:02AM
Nov-10-22 09:02AM
Nov-07-22 04:05PM
Oct-14-22 06:35PM
Sep-30-22 11:48AM
08:32AM Loading…
Sep-24-22 08:32AM
Sep-19-22 07:00AM
Sep-12-22 07:02AM
Sep-09-22 08:47AM
07:00AM
Aug-31-22 02:10PM
Aug-04-22 04:04PM
Jul-25-22 04:05PM
Jul-08-22 10:18AM
May-06-22 04:05PM
06:00PM Loading…
Apr-28-22 06:00PM
Apr-19-22 06:15PM
Apr-12-22 06:15PM
Apr-09-22 10:03AM
Mar-28-22 06:15PM
Mar-22-22 06:15PM
Mar-15-22 06:00PM
Mar-07-22 10:39AM
Mar-03-22 11:05AM
Mar-01-22 04:05PM
Feb-25-22 06:00PM
Feb-21-22 09:53AM
Feb-17-22 02:38AM
Feb-08-22 01:38PM
Feb-07-22 01:38PM
06:00PM Loading…
Feb-04-22 06:00PM
Feb-01-22 01:38PM
08:00AM
Jan-24-22 06:15PM
01:53PM
Jan-12-22 12:09PM
Jan-09-22 06:26AM
Jan-06-22 08:17AM
Jan-05-22 06:59AM
Jan-04-22 10:00AM
09:40AM
Dec-22-21 04:37PM
12:36PM
10:41AM
09:07AM
Dec-21-21 07:15PM
Dec-20-21 08:32AM
Dec-08-21 07:38PM
07:38PM
Nov-30-21 07:00AM
Nov-19-21 10:27AM
08:40AM
Nov-08-21 04:05PM
Oct-25-21 08:00AM
Oct-24-21 03:35PM
Sep-30-21 11:12AM
08:39AM
Sep-29-21 08:47AM
Aug-09-21 04:01PM
Jul-29-21 05:31PM
Jul-21-21 06:44AM
Jul-13-21 01:32AM
Jun-07-21 08:00AM
06:12AM
May-24-21 07:00AM
May-21-21 08:57AM
08:08AM
May-10-21 04:01PM
Apr-19-21 04:01PM
Mar-30-21 08:00AM
Mar-01-21 08:00AM
Feb-17-21 02:22AM
Jan-13-21 11:16PM
Jan-06-21 11:16AM
Dec-22-20 04:05PM
Dec-21-20 10:07AM
Dec-10-20 10:33PM
Nov-09-20 08:01AM
Nov-02-20 08:00AM
Oct-28-20 08:20PM
07:41AM
Oct-27-20 07:56PM
04:09PM
Oct-26-20 07:00AM
07:00AM
Oct-21-20 05:00PM
Aug-28-20 06:53AM
Aug-10-20 08:00AM
Jul-18-20 09:55AM
Jul-05-20 03:31PM
Jun-16-20 06:30PM
Jun-03-20 08:01AM
May-21-20 08:01AM
May-15-20 09:02AM
May-14-20 12:00PM
May-11-20 12:40PM
10:31AM
10:03AM
08:01AM
08:00AM
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Walker Paul EdwardDirectorSep 21Buy5.023,984,00019,999,6803,386,400Sep 23 04:35 PM
JANNEY DANIELDirectorSep 21Buy5.02475,0002,384,5002,546,147Sep 23 04:25 PM